Amvuttra

Amvuttra is a medicine used to treat polyneuropathy (nerve damage) caused by hereditary transthyretin-mediated (hATTR) amyloidosis, a disease in which abnormal proteins called amyloids build up in tissues around the body including around the nerves. Amvuttra is used in adult patients in the first two stages of the nerve damage (stage 1, when the patient has weakness in the legs but is able to walk unaided, and stage 2, when the patient can still walk but needs help). hATTR amyloidosis is rare, and Amvuttra was designated an ‘ [orphan medicine](/en/node/43119)’ (a medicine used in rare diseases) on 25 May 2018. Further information on the orphan designation can be found [here](/en/medicines/human/orphan-designations/eu-3-18-2026). Amvuttra contains the active substance vutrisiran.